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Figure	legends	
Figure	1.	Prevalence	of	injectable	hormonal	contraceptive	(IHC)	use	and	HIV	prevalence	by	
country.	Countries	are	coloured	according	to	HIV	prevalence[16-20]	and	IHC	use[2]	among	15-49	
year-old	women:	red	=	high	IHC	and	high	HIV;	pink	=	high	IHC	and	low	HIV;	orange	=	low	IHC	and	
high	HIV;	yellow	=	low	IHC	and	low	HIV.	HIV	prevalence	above	1%	and	IHC	prevalence	in	the	top	
quartile	globally	are	defined	as	high	and	all	values	below	these	thresholds	are	low.	HIV	prevalence	
data	was	unavailable	for	15-49	year-old	women	in	Brazil,	China,	the	Democratic	Republic	of	the	
Congo	(DRC)	and	Thailand	therefore	we	use	reported	HIV	prevalence	from	antenatal	clinics	for	
Brazil,[17]	DRC,[19]	and	Thailand[20]	and	adult	HIV	prevalence	for	China.[18]		
	
Figure	2.	
A.	Excess	HIV	infections	per	year	attributable	to	a	hypothesised	IHC-HIV	interaction.	Countries	are	
ranked	according	to	the	total	number	of	HIV	infections	per	year	that	would	be	attributed	to	a	
putative	IHC-HIV	interaction	with	effect	size	(1)	RR=1.2	and	(2)	RR=2.19.[5]	The	ten	countries	with	
the	highest	excess	infections	are	shown	together	with	selected	examples	from	different	regions.	
Country	rankings	out	of	116	countries	with	available	data	are	annotated	next	to	the	respective	bars.	
Data	for	all	other	countries	can	be	found	in	supplementary	table	2	(online).	
B.	Excess	live	births	per	year	resulting	from	cessation	of	all	IHC	use;	and	
C.	Excess	maternal	deaths	per	year	resulting	from	cessation	of	all	IHC	use.	It	is	assumed	that	all	
women	previously	using	IHC	are	transitioned	to	either	no	contraception	or	a	hypothetical	
alternative,	in	proportion	to	the	method	mix	reported	by	the	non-IHC-using	population	for	each	
country.[2]	Countries	are	ranked	according	to	the	excess	number	of	live	births	per	year	that	can	be	
attributed	to	cessation	of	all	IHC	use.	The	ten	countries	with	the	highest	numbers	of	excess	births	
are	shown	together	with	the	examples	from	fig.	2A.	Country	rankings	out	of	134	countries	with	
available	data	are	annotated	next	to	the	relevant	bars.	Data	for	all	other	countries	can	be	found	in	
supplementary	table	2	(online).	
	
Figure	3.	Change	in	the	number	of	net	maternal	and	HIV-related	deaths	resulting	from	cessation	of	
IHC	use.		
A.	Direction	of	change.	Countries	are	coloured	according	to	the	direction	of	change	in	the	net	
number	of	maternal	and	HIV-related	deaths	that	result	directly	from	stopping	IHC	use	assuming	(1)	
RR=1.2	and	(2)	RR=2.19:	red	=	expected	increase	in	net	maternal	and	HIV-related	deaths	(>0.5%	
under	both	RR	assumptions);	pink	=	change	in	net	deaths	is	dependent	on	the	effect	size	(>0.5%	
increase	only	when	RR=1.2);	cream	=	reductions	in	IHC	use	unlikely	to	provide	public	health	benefit	
in	terms	of	deaths	prevented	(<0.5%	change		with	both	estimates);	yellow	=	change	in	net	deaths	is	
dependent	on	the	effect	size	(>0.5%	decrease	only	when	RR	=	2.19);	green	=	expected	decrease	in	
net	deaths	(>0.5%	under	both	RR	assumptions);	grey	=	data	not	available.	
B.	Absolute	change.	The	change	in	net	maternal	and	HIV-related	deaths	on	cessation	of	all	IHC	use,	
assuming	(1)	RR=1.0	(yellow),	(2)	RR=1.2	(light	blue)	and	(3)	RR=2.19	(dark	blue),	shown	for	the	
countries	presented	in	fig.	2.	Data	for	all	other	countries	can	be	found	in	supplementary	table	2	
(online).	
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